" class="no-js "lang="en-US"> HEART UK - Medtech Alert
Sunday, July 05, 2026

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
HEART UK | Pharmtech Focus

HEART UK

About HEART UK

HEART UK

We are passionate about preventing early death caused by high cholesterol.

Over half the population have raised cholesterol and one in every two hundred and fifty people are born with an inherited high cholesterol condition, which means they are at accellerated risk of a heart attack or stroke.

Our vision is that the majority of UK adults will know their cholesterol levels, understand the impact and to be taking any necessary action.

HEART UK is here for anyone affected by raised cholesterol. We bring people together, provide information, support, education and campaign for improved identification & standards of care.